Timing & pharmacokinetics
How long does BPC-157 take to work?
Onset timing for BPC-157 varies in the clinical literature. Onset timing is not well-quantified in our dataset, refer to clinical citations on the main entry.
Onset
–
Half-life
–
Duration
–
Timing
AM/evening
Key facts
- typical dose
- 0.2–0.5 mg
- dose frequency
- 1-2 doses
- timing
- AM/evening
- with food
- n/a
- safety score
- 2/5
- evidence grade
- C
- class
- peptide
- PubMed citations
- 110
- legal status (US)
- Research-chemical category
- legal status (UK)
- Research-chemical category
- legal status (EU)
- Research-chemical category
- legal status (AU)
- Research-chemical category
- restrictions
- WADA (S0)
- primary mechanism
- Stimulates angiogenesis (new blood vessel formation) at injury sites, modulates nitric oxide and growth hormone receptor signalling, and increases collagen production in fibroblasts.
Onset window
BPC-157 onset times in the published literature vary widely. Refer to the citations on the main BPC-157 entry for compound-specific pharmacokinetic data.
Food effect:
Half-life and dosing frequency
Half-life is not characterised in our dataset.
Acute vs. chronic effect
Some nootropics work the first time you take them (BPC-157 may or may not). Others, adaptogens, racetams, and most botanicals targeting BDNF or NGF pathways, require 2–4 weeks of daily dosing before the full effect emerges.
If you don’t feel anything after a single dose and the compound is in the chronic-effect category, that is normal, extend the trial to 2–4 weeks before evaluating. If it is in the acute category and you feel nothing, consider dose, vendor sourcing, or whether the compound matches your goal.
Protocol note from the BPC-157 entry
Subcutaneous research use. Not approved for human consumption.
Mechanism, safety, and citations for BPC-157 are on the main reference page, see BPC-157. For full dose protocol see BPC-157 dosage. To check for stack-level pharmacokinetic conflicts, use the interaction checker.
Onset and pharmacokinetic data reflect the published literature for healthy adults at typical doses. Individual variation in absorption, metabolism (CYP genotype), and gut transit can shift onset by ±50%. This page is informational and not medical advice. See our full disclaimer.